You are here
As prescribed in Section 225 of the National Health Reform Act 2011, the objectives of the IHPA Work Program are to:
- set out IHPA’s work program for the coming year; and
- invite interested persons (including states and territories) to make submissions to the Pricing Authority about the Work Program up to 30 days after publication.
An extract of Section 225 of the Act is attached at Appendix 1.
Chimeric antigen receptor T cell therapy (CAR-T cell): guidelines for costing, counting and reconciliation of funding18 June 2020
The guidelines set out the scope, funding, costing, counting and reconciliation of funding for the chimeric antigen receptor T cell therapy (CAR-T cell) immunotherapy program using the Novartis CAR-T product Kymriah. The CAR-T program is for paediatric and young adults (up to 25 years) with Acute Lymphoblastic Leukaemia (ALL) who relapse or do not respond to initial therapy.
Following the completion of the 2016 Inter-Rater Reliability (IRR) study to test the consistency of clinician application of the mental health phase of care, the poor to fair reliability outcome led to the commencement of the refinement project.
The Independent Hospital Pricing Authority (IHPA) has developed the Australian Mental Health Care Classification Pricing Feasibility Report 2020–21 to provide an overview of the process undertaken by IHPA to shadow price admitted mental health services using the Australian Mental Health Care Classification (AMHCC) Version 1.0.